血管内大B细胞淋巴瘤免疫检查点相关基因的频繁遗传学改变
该研究通过对21例血管内大B细胞淋巴瘤(IVLBCL)患者进行血浆游离DNA(cfDNA)、人源异种移植瘤和骨髓肿瘤DNA的全外显子组测序,揭示了IVLBCL具有活化B细胞型弥漫大B细胞淋巴瘤(DLBCL)的遗传学特征,并频繁出现MYD88、CD79B、SETD1B和HLA-B突变以及PD-L1/PD-L2重排,提示免疫逃逸在IVLBCL发病中起重要作用。
要点
- IVLBCL中MYD88、CD79B、SETD1B和HLA-B突变频率分别为57%、67%、57%和57%。
- 38%的IVLBCL患者存在PD-L1/PD-L2重排,涉及3'非翻译区,与免疫逃逸相关。
- 血浆cfDNA浓度在IVLBCL中显著高于DLBCL和健康供者,可用于全外显子组测序。
核心结论
- IVLBCL具有活化B细胞型DLBCL的遗传学特征,并频繁出现免疫检查点相关基因的遗传学改变,提示免疫逃逸在IVLBCL发病中起重要作用,PD-1/PD-L1/PD-L2阻断可能成为治疗选择。
研究设计与样本
- 对21例IVLBCL患者进行全外显子组测序,样本来源包括血浆游离DNA(n=18)、人源异种移植瘤(n=4)和骨髓单个核细胞肿瘤DNA(n=2)。
主要发现
- IVLBCL中MYD88突变频率为57%,CD79B为67%,SETD1B为57%,HLA-B为57%,均高于结内DLBCL。
- 8例(38%)IVLBCL存在PD-L1/PD-L2重排,涉及3'非翻译区,与PD-L1/PD-L2过表达介导的免疫逃逸相关。
- IVLBCL血浆cfDNA浓度显著高于DLBCL(P < .0001)和健康供者(P = .0053)。
- 骨髓肿瘤DNA中检测到的大多数突变在cfDNA和异种移植瘤中均被成功捕获。
临床怎么用
- 血浆cfDNA可用于IVLBCL的基因检测,克服活检标本中肿瘤细胞稀少导致的材料不足问题。
- IVLBCL频繁出现PD-L1/PD-L2重排,提示PD-1/PD-L1/PD-L2阻断可能作为治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravascular large B-cell lymphoma (IVLBCL) is a unique type of extranodal lymphoma characterized by selective growth of tumor cells in small vessels without lymphadenopathy. Greater understanding of the molecular pathogenesis of IVLBCL is hampered by the paucity of lymphoma cells in biopsy specimens, creating a limitation in obtaining sufficient tumor materials. To uncover the genetic landscape of IVLBCL, we performed whole-exome sequencing (WES) of 21 patients with IVLBCL using plasma-derived cell-free DNA (cfDNA) (n = 18), patient-derived xenograft tumors (n = 4), and tumor DNA from bone marrow (BM) mononuclear cells (n = 2). The concentration of cfDNA in IVLBCL was significantly higher than that in diffuse large B-cell lymphoma (DLBCL) (P < .0001) and healthy donors (P = .0053), allowing us to perform WES; most mutations detected in BM tumor DNA were successfully captured in cfDNA and xenograft. IVLBCL showed a high frequency of genetic lesions characteristic of activated B-cell-type DLBCL, with the former showing conspicuously higher frequencies (compared with nodal DLBCL) of mutations in MYD88 (57%), CD79B (67%), SETD1B (57%), and HLA-B (57%). We also found that 8 IVLBCL (38%) harbored rearrangements of programmed cell death 1 ligand 1 and 2 (PD-L1/PD-L2) involving the 3' untranslated region; such rearrangements are implicated in immune evasion via PD-L1/PD-L2 overexpression. Our data demonstrate the utility of cfDNA and imply important roles for immune evasion in IVLBCL pathogenesis and PD-1/PD-L1/PD-L2 blockade in therapeutics for IVLBCL.
引用
- Shimada K, Yoshida K, Suzuki Y, et al. Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma. Blood. 2021. PMID: 33512416. doi:10.1182/blood.2020007245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。